Marketing services ethically and without stigma Patients are often first exposed to these medications through ads on Meta platforms (Facebook, Instagram) or TikTok, where many of the companies we reviewed were actively advertising
(2024, September) Retatrutide is a novel triple-agonist targeting GLP-1, GIP, and glucagon receptors, showing in phase 2 trials that it can deliver remarkably large weight losses (up to ~24% over 48 weeks in people with obesity) along with strong improvements in HbA1c, lipid profiles, liver fat (in NAFLD), insulin sensitivity, and other cardiometabolic markers
[DOI] [PubMed] [Google Scholar] 8.Li T., Zhao J., Cao H., Han X., Lu Y., Jiang F., Li X., Sun J., Zhou S., Sun Z., et al
This limited coverage can be attributed to the prevailing perception of obesity as primarily an aesthetic concern rather than a medical condition